Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
PyL6SEA2qgLMgmgH
Listen
